胆嚢がん治療法の世界市場2019-2023

◆英語タイトル:Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31864
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年8月26日
◆ページ数:133
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、胆嚢がん治療法の世界市場について調べ、胆嚢がん治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、胆嚢がん治療法の市場規模をセグメンテーション別(種類別(併用療法、単独療法)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は胆嚢がん治療法の世界市場規模が2019-2023期間中に年平均5%成長すると予測しています。
・サマリー
・レポートの範囲
・胆嚢がん治療法の市場状況
・胆嚢がん治療法の市場規模
・胆嚢がん治療法の市場予測
・胆嚢がん治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(併用療法、単独療法)
・胆嚢がん治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Gallbladder Cancer Therapeutics Market: About this market
Technavio’s gallbladder cancer therapeutics market considers sales from both combination therapy and monotherapy. Our analysis also considers the sales of gallbladder cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high therapeutic efficacy of these drugs will play a significant role in the combination therapy segment to maintain its market position. Also, our global gallbladder cancer therapeutics market report looks at factors such as strong incidence of gallbladder cancer in developing countries, rising risk factors for gall bladder cancer, and use of chemotherapy as a therapeutic approach. However, uncertainties in the side effect associated with chemotherapy, lack of diagnostic antigens for gallbladder cancer, and low incidence rate of disease in developed countries may hamper the growth of the global gallbladder cancer therapeutics industry over the forecast period.

Global Gallbladder Cancer Therapeutics Market: Overview

Rising risk factors for gallbladder cancer
Rise in the occurrence of cholelithiasis, chronic inflammation, and gall bladder polyps will increase the risk of developing gall bladder cancer, inducing the demand gallbladder cancer therapeutics. The rising availability of financial assistance programs is further helping patients in availing these high-cost treatments. This will lead to the expansion of the global gallbladder cancer therapeutics market at a CAGR of almost 5% during the forecast period.

The advent of targeted therapy
The global gallbladder cancer therapeutics market is witnessing the advent of immunotherapy as a potential therapeutic for the treatment of biliary tract cancer, including gallbladder cancer. The ongoing research in this is expected to facilitate the approval process of this drug. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global gallbladder cancer therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global gallbladder cancer therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gallbladder cancer therapeutics manufacturers, that include Bristol-Myers Squibb Co., Eli Lilly, and Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi.

Also, the gallbladder cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Combination therapy – Market size and forecast 2018-2023
• Monotherapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strong pipeline
• Advent of targeted therapy
• Strategic alliances
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Sanofi
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Some late-stage molecules for biliary tract cancer and global gallbladder cancer
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Combination therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Combination therapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Incidence rate of gallbladder cancer in various developing countries – 2015
Exhibit 44: Frequency of side effects associated with chemotherapy
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 52: Bristol-Myers Squibb Co. – Business segments
Exhibit 53: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 54: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 55: Bristol-Myers Squibb Co. – Key offerings
Exhibit 56: Bristol-Myers Squibb Co. – Key customers
Exhibit 57: Eli Lilly and Co. – Vendor overview
Exhibit 58: Eli Lilly and Co. – Business segments
Exhibit 59: Eli Lilly and Co. – Organizational developments
Exhibit 60: Eli Lilly and Co. – Geographic focus
Exhibit 61: Eli Lilly and Co. – Segment focus
Exhibit 62: Eli Lilly and Co. – Key offerings
Exhibit 63: Eli Lilly and Co. – Key customers
Exhibit 64: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 70: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 71: Pfizer Inc. – Vendor overview
Exhibit 72: Pfizer Inc. – Business segments
Exhibit 73: Pfizer Inc. – Organizational developments
Exhibit 74: Pfizer Inc. – Geographic focus
Exhibit 75: Pfizer Inc. – Segment focus
Exhibit 76: Pfizer Inc. – Key offerings
Exhibit 77: Pfizer Inc. – Key customers
Exhibit 78: Sanofi – Vendor overview
Exhibit 79: Sanofi – Business segments
Exhibit 80: Sanofi – Organizational developments
Exhibit 81: Sanofi – Geographic focus
Exhibit 82: Sanofi – Segment focus
Exhibit 83: Sanofi – Key offerings
Exhibit 84: Sanofi – Key customers
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: Definition of market positioning of vendors



【掲載企業】

Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., and Sanofi.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[胆嚢がん治療法の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆